Company Description
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction.
In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials.
Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1997 |
| IPO Date | Apr 29, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 673 |
| CEO | Robert Blum |
Contact Details
Address: 350 Oyster Point Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 624 3000 |
| Website | cytokinetics.com |
Stock Details
| Ticker Symbol | CYTK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001061983 |
| CUSIP Number | 23282W605 |
| ISIN Number | US23282W6057 |
| Employer ID | 94-3291317 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert I. Blum | Chief Executive Officer, President and Director |
| Sung H. Lee | Executive Vice President and Chief Financial Officer |
| Dr. Fady Ibraham Malik FACC, M.D., Ph.D. | Executive Vice President of Research and Development |
| Andrew M. Callos | Executive Vice President and Chief Commercial Officer |
| Dr. James H. Sabry M.D., Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Dr. James A. Spudich Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Jeff Lotz | Vice President of Sales and Operations |
| Holly Laughlin | Vice President of Accounting and Corporate Controller |
| Steven M. Cook J.D. | Senior Vice President of Global Supply Chain Operations and Technical Operations |
| Jeffrey J. Hessekiel J.D. | Executive Vice President, Chief Legal and Administrative Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2026 | 144 | Filing |
| Mar 16, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Feb 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | 8-K | Current Report |
| Jan 2, 2026 | 144 | Filing |
| Dec 29, 2025 | 144 | Filing |